Clinical Research Directory
Browse clinical research sites, groups, and studies.
Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer
Sponsor: PT. Prodia Stem Cell Indonesia
Summary
The purpose of this study is to determine the safety and potential of dendritic cells therapy and secretomes therapy for advanced nasopharyngeal cancer.
Official title: Safety and Efficacy of Adjuvant Therapy of Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2022-04-30
Completion Date
2026-02-28
Last Updated
2026-02-25
Healthy Volunteers
No
Conditions
Interventions
Placebo (Aqua Pro-Injection)
Treatment with Aqua Pro-Injection 2 cc 2 times injection, interval 2 days (via Intramuscular).
Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy)
Treatment with Aqua Pro-Injection 2 cc, and then followed by Auto DC, interval 2 days (via Intramuscular)
Combination of Auto DC and Allo-Dendritic Cell-Secretome (Allogeneic Dendritic Cell-Secretome as Adjuvant Therapy)
Treatment with Allo-DC-Secretome 2 cc, and then followed by Auto DC, interval 2 days (via Intramuscular)
Locations (1)
PT Prodia StemCell Indonesia
Jakarta, Indonesia